IN A010
Alternative Names: IN-A010Latest Information Update: 24 Jan 2023
At a glance
- Originator HK inno.N
- Class Antiglaucomas; Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Glaucoma; Non-alcoholic steatohepatitis
Highest Development Phases
- Phase II Glaucoma; Non-alcoholic steatohepatitis
Most Recent Events
- 24 Jan 2023 IN A010 is still in phase II trial for Glaucoma in South Korea (unspecified route) (HK inno.N pipeline, January 2023)
- 24 Jan 2023 IN A010 is still in phase II trial for Non-alcoholic steatohepatitis in South Korea (unspecified route) (HK inno.N pipeline, January 2023)
- 15 Jan 2021 Phase-II clinical trials in Glaucoma in South Korea (unspecified route) (HK inno.N pipeline, January 2021)